Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCVS Caremark Cosentyx Prior Auth Policy | OpenPaye…
    Ask Trek AI about this page
    CurrentCVS CaremarkPolicy 2017-A

    Specialty Guideline Management Cosentyx

    Customize your policy alerts

    Sign up for cvs_caremark Policy 2017-A alerts

    Get alerted when Policy 2017-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization coverage for Cosentyx (secukinumab) for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, enthesitis-related arthritis, and hidradenitis suppurativa when applicable age, prior-treatment, clinical-response, prescriber, and documentation requirements are met.

    Policy Summary
    PayerCVS Caremark
    PolicySpecialty Guideline Management Cosentyx
    Policy CodePolicy 2017-A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit the required clinical documentation to initiate prior authorization review.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6FDA-approved covered indications
    12 monthsInitial authorization period
    12 monthsContinuation authorization period
    2 yearsYoungest covered age

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    Continuation Therapy — Psoriatic Arthritis

    Authorization of 12 months may be granted when ALL of the following criteria are met:

    ALL of the following

    • Member is 2 years of age or older, including new members.
    • Member is using the requested medication for psoriatic arthritis.
    • Member achieves or maintains a positive clinical response, evidenced by low disease activity or improvement in signs and symptoms of the condition.
    • There is improvement from baseline in at least one of the following: number of swollen joints, number of tender joints, dactylitis, enthesitis, axial disease, skin and/or nail involvement, functional status, or C-reactive protein (CRP).

    Continuation Therapy — Ankylosing Spondylitis

    Authorization of 12 months may be granted when ALL of the following criteria are met:

    ALL of the following

    • Member is 12 years of age or older, including new members.
    • Member is using the requested medication for ankylosing spondylitis.
    • Member achieves or maintains a positive clinical response, evidenced by low disease activity or improvement in signs and symptoms of the condition.
    • There is improvement from baseline in at least one of the following: functional status, total spinal pain, inflammation (e.g., morning stiffness), swollen joints, tender joints, or C-reactive protein (CRP).

    Continuation Therapy — Non-radiographic Axial Spondyloarthritis

    Authorization of 12 months may be granted when ALL of the following criteria are met:

    ALL of the following

    • Member is an adult, including a new member.
    • Member is using the requested medication for non-radiographic axial spondyloarthritis.
    • Member achieves or maintains a positive clinical response, evidenced by low disease activity or improvement in signs and symptoms of the condition.
    • There is improvement from baseline in at least one of the following: functional status, total spinal pain, inflammation (e.g., morning stiffness), swollen joints, tender joints, or C-reactive protein (CRP).

    Continuation Therapy — Enthesitis-related Arthritis

    Authorization of 12 months may be granted when ALL of the following criteria are met:

    ALL of the following

    • Member is 4 years of age or older, including a new member.
    • Member is using the requested medication for active enthesitis-related arthritis.
    • Member achieves or maintains a positive clinical response, evidenced by low disease activity or improvement in signs and symptoms of the condition.
    • There is improvement from baseline in at least one of the following: number of flares, number of joints with active arthritis (e.g., swelling or pain), number of joints with limited movement, dactylitis, or enthesitis.

    General Requirements for All Indications

    The following requirements apply to all indications:

    ALL of the following

    • Member has been evaluated for tuberculosis (TB) infection prior to initiation of treatment with a biologic or targeted synthetic drug associated with an increased risk of TB.
    • Member cannot use the requested medication concomitantly with any other biologic drug or targeted synthetic drug for the same indication.

    All other indications are considered experimental/investigational and not medically necessary.

    Cosentyx is not medically necessary when used concomitantly with any other biologic drug or targeted synthetic drug for the same indication.

    Cosentyx is not medically necessary outside the specified covered FDA-approved indications: moderate to severe plaque psoriasis, active psoriatic arthritis, active ankylosing spondylitis, active non-radiographic axial spondyloarthritis with objective signs of inflammation, active enthesitis-related arthritis, and moderate to severe hidradenitis suppurativa.

    Initial Therapy Criteria

    Plaque psoriasis — eligible members age 6 years or older and condition-specific criteria

    Authorization of 12 months may be granted for eligible members 6 years of age or older.

    Plaque psoriasis: Member is 6 years of age or older and either has prior biologic or targeted synthetic drug use indicated for moderate to severe plaque psoriasis or meets a qualifying plaque psoriasis severity or treatment pathway.Age >= 6 years; authorization period 12 months

    Psoriatic arthritis — eligible members age 2 years or older and condition-specific criteria

    Authorization of 12 months may be granted for eligible members 2 years of age or older.

    Psoriatic arthritis: Member is 2 years of age or older and either has prior biologic or targeted synthetic drug use indicated for active psoriatic arthritis or has active disease meeting a qualifying conventional-treatment, enthesitis or axial-disease, or severe-disease pathway.Age >= 2 years; authorization period 12 months

    Ankylosing spondylitis — eligible members age 12 years or older and condition-specific criteria

    Authorization of 12 months may be granted for eligible members 12 years of age or older.

    Ankylosing spondylitis: Member is 12 years of age or older and either has prior biologic or targeted synthetic drug use indicated for active ankylosing spondylitis or has inadequate response to at least two NSAIDs or intolerance or contraindication to two or more NSAIDs.Age >= 12 years; authorization period 12 months

    Non-radiographic axial spondyloarthritis — eligible adult members and condition-specific criteria

    Authorization of 12 months may be granted for eligible adult members.

    Non-radiographic axial spondyloarthritis: Member is an adult and either has prior biologic or targeted synthetic drug use indicated for active non-radiographic axial spondyloarthritis or has inadequate response to at least two NSAIDs or intolerance or contraindication to two or more NSAIDs.Adult; authorization period 12 months

    Enthesitis-related arthritis — eligible members age 4 years or older and condition-specific criteria

    Authorization of 12 months may be granted for eligible members 4 years of age or older.

    Enthesitis-related arthritis: Member is 4 years of age or older, has at least three active joints and at least one site of active enthesitis at baseline or documented by history, and has either inadequate response to NSAIDs, sulfasalazine, or methotrexate or intolerance or contraindication to those therapies.Age >= 4 years; >=3 active joints; >=1 active enthesitis site; authorization period 12 months

    Hidradenitis suppurativa — eligible members age 12 years or older and condition-specific criteria

    Authorization of 12 months may be granted for eligible members 12 years of age or older.

    Hidradenitis suppurativa: Member is 12 years of age or older and has moderate to severe hidradenitis suppurativa with either prior biologic use, inadequate response to an oral antibiotic used for at least 8 weeks, or intolerance or contraindication to such oral antibiotics.Age >= 12 years; authorization period 12 months

    Continuation Criteria

    Plaque psoriasis continuation — age, indication, and positive clinical response

    Authorization of 12 months may be granted for members 6 years of age or older using Cosentyx for moderate to severe plaque psoriasis who achieve or maintain a positive clinical response.

    Plaque psoriasis continuation: Member is 6 years of age or older, uses Cosentyx for moderate to severe plaque psoriasis, and achieves or maintains a positive clinical response shown by low disease activity or improvement in signs and symptoms, including reduced BSA affected or improvement in itching, redness, flaking, scaling, burning, cracking, or pain from baseline.Age >= 6 years; authorization period 12 months

    Psoriatic arthritis continuation — age, indication, and positive clinical response

    Authorization of 12 months may be granted for members 2 years of age or older using Cosentyx for psoriatic arthritis who achieve or maintain a positive clinical response.

    Psoriatic arthritis continuation: Member is 2 years of age or older, uses Cosentyx for psoriatic arthritis, and achieves or maintains a positive clinical response shown by low disease activity or improvement from baseline in swollen joints, tender joints, dactylitis, enthesitis, axial disease, skin or nail involvement, functional status, or CRP.Age >= 2 years; authorization period 12 months

    Ankylosing spondylitis continuation — age, indication, and positive clinical response

    Authorization of 12 months may be granted for members 12 years of age or older using Cosentyx for ankylosing spondylitis who achieve or maintain a positive clinical response.

    Ankylosing spondylitis continuation: Member is 12 years of age or older, uses Cosentyx for ankylosing spondylitis, and achieves or maintains a positive clinical response shown by low disease activity or improvement from baseline in functional status, total spinal pain, inflammation such as morning stiffness, swollen joints, tender joints, or CRP.Age >= 12 years; authorization period 12 months

    Non-radiographic axial spondyloarthritis continuation — adult indication and positive clinical response

    Authorization of 12 months may be granted for adult members using Cosentyx for non-radiographic axial spondyloarthritis who achieve or maintain a positive clinical response.

    Non-radiographic axial spondyloarthritis continuation: Member is an adult, uses Cosentyx for non-radiographic axial spondyloarthritis, and achieves or maintains a positive clinical response shown by low disease activity or improvement from baseline in functional status, total spinal pain, inflammation such as morning stiffness, swollen joints, tender joints, or CRP.Adult; authorization period 12 months

    Ankylosing spondylitis continuation — including new members

    Authorization of 12 months may be granted for members age 12 years or older, including new members, using Cosentyx for ankylosing spondylitis who achieve or maintain a positive clinical response.

    Ankylosing spondylitis: Member is at least 12 years of age, uses Cosentyx for ankylosing spondylitis, and achieves or maintains a positive clinical response shown by low disease activity or improvement in signs and symptoms with improvement from baseline in functional status, total spinal pain, inflammation, swollen joints, tender joints, or CRP.Age >= 12 years; 12-month authorization

    Includes new members.

    Non-radiographic axial spondyloarthritis continuation — including new adult members

    Authorization of 12 months may be granted for adult members, including new members, using Cosentyx for non-radiographic axial spondyloarthritis who achieve or maintain a positive clinical response.

    Non-radiographic axial spondyloarthritis: Member is an adult, uses Cosentyx for non-radiographic axial spondyloarthritis, and achieves or maintains a positive clinical response shown by low disease activity or improvement in signs and symptoms with improvement from baseline in functional status, total spinal pain, inflammation, swollen joints, tender joints, or CRP.Adult; 12-month authorization

    Includes new members.

    Enthesitis-related arthritis continuation — members age 4 years or older

    Authorization of 12 months may be granted for members age 4 years or older, including new members, using Cosentyx for active enthesitis-related arthritis who achieve or maintain a positive clinical response.

    Enthesitis-related arthritis: Member is at least 4 years of age, uses Cosentyx for active enthesitis-related arthritis, and achieves or maintains a positive clinical response shown by low disease activity or improvement in signs and symptoms with improvement in number of flares, active joints, joints with limited movement, dactylitis, or enthesitis.Age >= 4 years; 12-month authorization

    Includes new members.

    Hidradenitis suppurativa continuation — members age 12 years or older

    Authorization of 12 months may be granted for members age 12 years or older, including new members, using Cosentyx for moderate to severe hidradenitis suppurativa who achieve or maintain a positive clinical response.

    Hidradenitis suppurativa: Member is at least 12 years of age, uses Cosentyx for moderate to severe hidradenitis suppurativa, and achieves or maintains a positive clinical response shown by low disease activity or improvement in signs and symptoms with at least one improvement from baseline or on a disease severity assessment tool, including abscess or inflammatory nodule count, sinus tracts or scarring, inflammatory lesion frequency, pain, suppuration, relapse frequency, quality of life, or disease severity assessment.Age >= 12 years; moderate to severe disease; 12-month authorization

    Includes new members.

    Prior Treatment Requirements

    IndicationPrior treatment pathwayQualifying alternative
    Plaque psoriasisPrior biologic or targeted synthetic drug indicated for moderate to severe plaque psoriasisModerate to severe disease with crucial body-area involvement; or at least 10% BSA; or at least 3% BSA with inadequate response or intolerance to phototherapy, methotrexate, cyclosporine, or acitretin, or a clinical reason to avoid those pharmacologic treatments
    IndicationPrior treatment pathwayQualifying alternative
    Psoriatic arthritisPrior biologic or targeted synthetic drug indicated for active psoriatic arthritisMild to moderate disease with inadequate response, intolerance, or contraindication to methotrexate, leflunomide, or another conventional synthetic drug; or enthesitis or predominantly axial disease; or severe disease
    IndicationPrior treatment pathwayQualifying alternative
    Ankylosing spondylitis or non-radiographic axial spondyloarthritisPrior biologic or targeted synthetic drug indicated for the applicable conditionInadequate response to at least two NSAIDs, or intolerance or contraindication to two or more NSAIDs
    IndicationPrior treatment pathwayQualifying alternative
    Enthesitis-related arthritisPrior biologic for active enthesitis-related arthritisInadequate response to NSAIDs, sulfasalazine, or methotrexate, or intolerance or contraindication to those therapies
    IndicationPrior treatment pathwayQualifying alternative
    Hidradenitis suppurativaPrior biologic indicated for moderate to severe hidradenitis suppurativaInadequate response to an oral antibiotic used for hidradenitis suppurativa for at least 8 weeks, or intolerance or contraindication to such oral antibiotics

    Clinical Thresholds and Treatment Parameters

    Plaque psoriasis body surface area
    Extensive disease thresholdAt least 10% of body surface area (BSA) is affected.
    Limited BSA thresholdAt least 3% of BSA is affected.
    Qualifying treatment history for 3% BSAWith at least 3% BSA affected, the member must have an inadequate response or intolerance to phototherapy or methotrexate, cyclosporine, or acitretin, or a clinical reason to avoid those pharmacologic treatments.
    Enthesitis-related arthritis active disease
    Active joint thresholdAt least three active joints must be involved.
    Active enthesitis thresholdAt least one site of active enthesitis must be present.
    Timing or documentationActive disease must be demonstrated at baseline or documented by history.
    Hidradenitis suppurativa oral antibiotic trial
    Minimum oral antibiotic trialAt least 8 weeks.
    Required treatment outcomeThe member must have an inadequate response to an oral antibiotic used to treat hidradenitis suppurativa.
    Examples of oral antibioticsExamples include clindamycin, metronidazole, moxifloxacin, rifampin, and tetracyclines.
    NSAID trial for ankylosing spondylitis or non-radiographic axial spondyloarthritis
    Inadequate response pathwayInadequate response to at least two nonsteroidal anti-inflammatory drugs (NSAIDs).
    Intolerance pathwayIntolerance to two or more NSAIDs.
    Contraindication pathwayContraindication to two or more NSAIDs.

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required to initiate Cosentyx coverage. Covered FDA-approved indications include moderate to severe plaque psoriasis, active psoriatic arthritis, active ankylosing spondylitis, active non-radiographic axial spondyloarthritis with objective inflammation, active enthesitis-related arthritis, and moderate to severe hidradenitis suppurativa when all applicable approval criteria are met and no exclusions apply.

    • Document the covered indication, applicable age requirement, clinical criteria, prior treatment history, and response or reason therapy was avoided.
    • Coverage is subject to exclusion of unapproved indications, concurrent same-indication biologic or targeted synthetic therapy, and other unmet criteria.
    Prior Authorization

    Prescriber Specialty Requirement

    Cosentyx must be prescribed by, or prescribed in consultation with, the specialty required for the indication.

    • Plaque psoriasis: dermatologist.
    • Psoriatic arthritis and hidradenitis suppurativa: rheumatologist or dermatologist.
    • Ankylosing spondylitis, non-radiographic axial spondyloarthritis, and enthesitis-related arthritis: rheumatologist.
    Prior Authorization

    Continuation Authorization

    Continuation authorization may be granted for 12 months when the member meets the age and indication requirements and documentation shows a positive clinical response, evidenced by low disease activity or improvement in disease signs and symptoms.

    • Plaque psoriasis: members age 6 or older; reduced affected BSA or improvement in itching, redness, flaking, scaling, burning, cracking, or pain.
    • Psoriatic arthritis: members age 2 or older; improvement in swollen or tender joints, dactylitis, enthesitis, axial disease, skin or nail involvement, functional status, or CRP.
    • Ankylosing spondylitis: members age 12 or older; improvement in functional status, spinal pain, inflammation or morning stiffness, swollen or tender joints, or CRP.
    • Non-radiographic axial spondyloarthritis: adults; improvement in functional status, spinal pain, inflammation or morning stiffness, swollen or tender joints, or CRP.
    • Enthesitis-related arthritis: members age 4 or older; improvement in flares, active or limited-motion joints, dactylitis, or enthesitis.
    • Hidradenitis suppurativa: members age 12 or older; reduction in abscesses or inflammatory nodules, new sinus tracts or scarring, inflammatory lesions, pain, suppuration, relapses, or disease severity, or improvement in quality of life.
    Billing Rule

    Dosing Limits

    Approvals may be subject to dosing limits consistent with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

    • Confirm the requested dose and frequency comply with applicable labeling, compendial, and evidence-based limits.
    Step Therapy

    Plaque Psoriasis Prior Treatment

    For plaque psoriasis, document the required prior treatment pathway before requesting Cosentyx.

    • Member age 6 or older and previously received a biologic or targeted synthetic drug indicated for moderate to severe plaque psoriasis; or
    • For moderate to severe disease, document involvement of crucial body areas, at least 10% BSA, or at least 3% BSA plus inadequate response or intolerance to phototherapy or methotrexate, cyclosporine, or acitretin.
    • If applicable therapy is not advisable, document the clinical reason to avoid it.
    Step Therapy

    Psoriatic Arthritis Prior Treatment

    For psoriatic arthritis, document the applicable conventional, biologic, or targeted synthetic treatment pathway.

    • Member age 2 or older and previously received a biologic or targeted synthetic drug indicated for active psoriatic arthritis; or
    • For mild to moderate disease, document inadequate response to an adequate dose and duration of methotrexate, leflunomide, or another conventional synthetic drug such as sulfasalazine; intolerance or contraindication to those therapies; or enthesitis or predominantly axial disease.
    • Severe disease also meets the stated disease-severity pathway.
    Step Therapy

    Axial Spondyloarthritis Prior Treatment

    For ankylosing spondylitis or non-radiographic axial spondyloarthritis, document the applicable biologic, targeted synthetic, or NSAID treatment pathway.

    • Ankylosing spondylitis: member age 12 or older with prior biologic or targeted synthetic therapy, or inadequate response to at least two NSAIDs or intolerance/contraindication to two or more NSAIDs.
    • Non-radiographic axial spondyloarthritis: adult with prior biologic or targeted synthetic therapy, or inadequate response to at least two NSAIDs or intolerance/contraindication to two or more NSAIDs.
    Step Therapy

    Enthesitis-Related Arthritis Prior Treatment

    For enthesitis-related arthritis, document the required disease activity and prior treatment pathway.

    • Member age 4 or older with prior biologic therapy for active enthesitis-related arthritis; or
    • Active disease includes at least three active joints and at least one site of active enthesitis at baseline or documented by history, plus inadequate response to NSAIDs, sulfasalazine, or methotrexate, or intolerance/contraindication to those therapies.
    Step Therapy

    Hidradenitis Suppurativa Prior Treatment

    For hidradenitis suppurativa, document the required biologic or oral-antibiotic treatment pathway.

    • Member age 12 or older with prior biologic therapy for moderate to severe hidradenitis suppurativa; or
    • Document inadequate response to an oral antibiotic used for at least 8 weeks, such as clindamycin, metronidazole, moxifloxacin, rifampin, or a tetracycline.
    • An intolerance or contraindication to appropriate oral antibiotics may satisfy the pathway when documented.
    Documentation Required

    Initial Plaque Psoriasis Documentation

    For an initial plaque psoriasis request, submit chart notes or medical records documenting the affected areas and the affected body surface area (BSA), when applicable.

    • Include prior medications tried and response when applicable, or the clinical reason a therapy is not advisable.
    Documentation Required

    Continuation Plaque Psoriasis Documentation

    For continuation plaque psoriasis requests, submit documentation showing decreased affected BSA and/or improvement in signs and symptoms.

    • Chart notes or medical records should support the change from baseline and ongoing clinical benefit.
    Documentation Required

    Initial Non-Psoriasis Documentation

    For initial requests for psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, enthesitis-related arthritis, or hidradenitis suppurativa, submit clinical records supporting previous medications tried, when applicable, including response to therapy.

    • If prior therapy is not advisable, document the clinical reason to avoid it.
    Documentation Required

    Continuation Non-Psoriasis Documentation

    For continuation requests for psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, enthesitis-related arthritis, or hidradenitis suppurativa, submit chart notes or medical records supporting a positive clinical response.

    • Document response from baseline using indication-specific disease activity, signs, symptoms, or functional measures.
    Documentation Required

    Indication and Clinical Response

    Confirm and document the covered indication and applicable age requirement, and provide indication-specific evidence of response for continuation requests.

    • Initial requests must establish the applicable FDA-approved indication and age threshold.
    • Continuation requests must show low disease activity or improvement from baseline using the applicable clinical measures for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, enthesitis-related arthritis, or hidradenitis suppurativa.
    Documentation Required

    Tuberculosis Evaluation

    Before initiating Cosentyx or another biologic or targeted synthetic drug associated with increased tuberculosis risk, document that the member was evaluated for tuberculosis infection.

    • Include the pre-treatment TB evaluation in the clinical record.
    Billing Rule

    Concurrent Therapy Review

    Review the member's medication list and confirm that Cosentyx will not be used concomitantly with another biologic drug or targeted synthetic drug for the same indication.

    • Document the concurrent-therapy review before treatment initiation and during authorization review.
    Denial Risk

    Unapproved Indication

    All indications other than the stated FDA-approved indications are considered experimental/investigational and not medically necessary under this policy.

    • Do not submit an authorization request for an unapproved indication unless the policy is updated to include that use.
    Denial Risk

    Failure to Meet Initial Criteria

    Initial authorization may be denied when the member does not meet the applicable age, disease-severity, indication, or prior-treatment requirements.

    • Examples include age below the indication-specific threshold, insufficient plaque psoriasis BSA or affected-area criteria, no required prior biologic or targeted synthetic therapy, failure to meet conventional-treatment or NSAID requirements, or failure to document required active disease.
    • A documented intolerance, contraindication, or clinical reason to avoid required therapy must support an exception pathway.
    Denial Risk

    No Documented Clinical Response

    Continuation authorization may be denied when records do not document a positive clinical response or ongoing benefit from Cosentyx.

    • Submit indication-specific improvement from baseline, such as reduced BSA or psoriasis symptoms; improved joint, axial, enthesitis, inflammatory, functional, or CRP measures; or other response measures specified for the indication.
    Denial Risk

    Prescriber Specialty Requirement

    Requests may be denied when the prescriber does not meet the required specialty or consultation requirement for the indication.

    • Ensure the prescription is issued by, or the record documents consultation with, the required dermatologist and/or rheumatologist.
    Denial Risk

    No Pre-Treatment Tuberculosis Evaluation

    Requests may be denied when there is no documented pre-treatment evaluation for tuberculosis infection before use of a biologic or targeted synthetic drug associated with increased TB risk.

    • Include evidence of the TB evaluation in the submitted records.
    Denial Risk

    Concomitant Biologic or Targeted Synthetic Therapy

    Requests may be denied when Cosentyx is used concomitantly with another biologic drug or targeted synthetic drug for the same indication.

    • Review and document discontinuation or absence of same-indication concurrent therapy.
    Denial Risk

    Failure to Meet Continuation Criteria

    Continuation requests may be denied when the member does not meet the applicable age or covered-indication requirement or when records do not establish the required positive clinical response.

    • Maintain documentation of indication-specific improvement from baseline and ongoing low disease activity or improvement in signs and symptoms.
    • For continuation, authorization is generally limited to 12 months when all applicable criteria are met.

    Policy Background

    Cosentyx (secukinumab) is covered for specified inflammatory and immune-mediated conditions, including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, enthesitis-related arthritis, and hidradenitis suppurativa. Coverage is subject to indication-specific age, disease severity, prior-treatment history, and clinical-response requirements, with separate pathways for initial and continuation therapy.

    Clinical Definitions

    Non-radiographic axial spondyloarthritis
    ConditionAxial spondyloarthritis.
    Radiographic distinctionWithout definitive radiographic evidence.
    Key findingWithout definitive radiographic evidence of sacroiliitis.
    Enthesitis-related arthritis
    ConditionArthritis.
    Associated featureAssociated with enthesitis.
    PopulationOccurs in children or adolescents.
    Policy Summary
    PayerCVS Caremark
    PolicySpecialty Guideline Management Cosentyx
    Policy CodePolicy 2017-A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit the required clinical documentation to initiate prior authorization review.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaContinuation CriteriaPrior Treatment RequirementsClinical Thresholds and Treatment ParametersAuthorization, Documentation, and Denial RisksPolicy BackgroundClinical Definitions